RCMI Coordinating Center (RCMI CC) Header Logo

Prediction of improved therapeutics for fabry disease patients generated by mutagenesis of the a-galactosidase A active site, dimer interface, and glycosylation region.

Stokes ES, Gilchrist ML, Calhoun DH. Prediction of improved therapeutics for fabry disease patients generated by mutagenesis of the a-galactosidase A active site, dimer interface, and glycosylation region. Protein Expr Purif. 2020 11; 175:105710.

View in: PubMed

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support